PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Phenylbutazone→

Phenylbutazone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50-33-9
Molecular formula
C19H20N2O2
Molecular weight
308.3743 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pyrazolidinedione derivative
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis, reducing inflammatory mediators and producing anti-inflammatory, analgesic and antipyretic effects. This is a class-level pharmacological description; exact clinical use is restricted by species and product authorisation.
Indications / reported uses
  • Veterinary use: relief of inflammatory conditions associated with the musculoskeletal system in dogs and horses under applicable veterinary authorisations. Certain equine oral formulations are not for use in horses intended for human consumption. It is not a general human therapeutic indication.

Sources: US FDA Animal Drugs at FDA — Phenylbutazone boluses, horses only · US eCFR 21 CFR 520.1720e — Phenylbutazone powder (horses) · US eCFR 21 CFR 522.1720 — Phenylbutazone injectable (dogs and horses) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Phenylbutazone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenylbutazone Permitted Daily Exposure (PDE) report (the Phenylbutazone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenylbutazone Occupational Exposure Limit (OEL) report (the Phenylbutazone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.